One of the co-targeting strategies currently used in clinical practice includes targeting of different epitopes on the same receptor overexpressed on cancer cells, e.g., the two mAbs trastuzumab and pertuzumab, both targeting HER2, as first-line treatment of advanced breast cancer [63]. This evidence concerns the gene ERBB2 and breast cancer.